Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Jesús Duque-Afonso*, Jürgen Finke, Maud Ngoya, Jacques Emmanuel Galimard, Charles Craddock, Kavita Raj, Adrian Bloor, Emma Nicholson, Matthias Eder, Orchard Kim, Thomas Valerius, John A. Snowden, Eleni Tholouli, Charles Crawley, Matthew Collin, Keith M.O. Wilson, Alain Gadisseur, Rachel Protheroe, Eva Maria Wagner-Drouet, Bipin N. SavaniAlexandros Spyridonidis, Fabio Ciceri, Arnon Nagler, Mohamad Mohty*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology